Anxiety and Depression in COPD; Prevalence, Detection and Prognosis

COPD Clinical Trial

Official title:

Anxiety and Depression in COPD; Prevalence, Detection and Prognosis

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04427579
• Other study ID #: 2018/149
• Status: Active, not recruiting
• Start date: June 15, 2018
• Est. completion date: December 2025

Study information

• Verified date: June 2020
• Source: University Hospital, Akershus
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The current cohort study of 300 stable COPD patients aims to assess the following topics:

• The prevalence of anxiety and depressive disorders in patients with COPD

• The screening properties of Hospital Anxiety and Depression Scale in patients with COPD

• The prognostic influence by anxiety or depressive symptoms and anxiety or depressive disorder.

• whether characterization of 1) affective aspects of dyspnea symptoms or 2) persistent styles of thinking (worry or rumination) and metacognitions that drive these may improve the current recommendation of screening for anxiety and depression in COPD in relation to its clinical relevance on functional status and three year outcome

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 200
• Est. completion date: December 2025
• Est. primary completion date: December 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participant in in-hospital pulmonary rehabilitation at LHL-hospital Gardermoen

• Diagnosis of COPD

Exclusion Criteria:

• Acute exacerbated phase of COPD

Related Conditions & MeSH terms

• Anxiety Disorders
• COPD
• Depression
• Depressive Disorder
• Disease

Locations

Country	Name	City	State
Norway	LHL-hospital Gardermoen	Jessheim

Sponsors (4)

Lead Sponsor	Collaborator
University Hospital, Akershus	LHL Hospital Gardermoen, Priory Hospital Altrincham, University of Oslo

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	The prevalence of anxiety disorder	Clinically diagnosed anxiety disorders	1 year
Other	The prevalence of depressive disorder	Clinically diagnosed depressive disorder	1 year
Primary	COPD exacerbation rate	The number of moderate or severe exacerbations	3 years
Primary	Mortality rate	The number of deaths	3 years
Secondary	Assessment of Health-related Quality of Life With RAND-36	The total score and subscale scores on RAND 36	3 years